AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2023-11-01 DOI:10.1158/2643-3230.BCD-23-0187

Carlos L Arteaga, John L Cleveland, Margaret Foti, Ruben A Mesa, Louis M Weiner, Cheryl L Willman, David A Tuveson

引用次数: 0

Abstract

Summary: Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing resources, developing national demonstration projects, and driving innovation that impacts cancer science, cancer care delivery, and science and health policy.

查看原文本刊更多论文

癌症中心联盟：促进合作和创新，促进患者的救生科学发现。

来自美国癌症中心的癌症基础和临床研究发现显著改善了许多癌症患者的预后。尽管我们在对抗这种复杂疾病方面取得了进展，但各种形式的癌症仍然是一个重大的公共卫生挑战，直接或间接地影响着几乎每个美国人的生活。新成立的AACR癌症中心联盟将通过提供一个持续的机制来转移新知识、共享资源、开发国家示范项目，并推动创新，从而影响癌症科学、癌症护理以及科学和卫生政策，从而加快发现的步伐。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.